Marisa Fernández

Marisa Fernández

Auto-generated profile, based on publicly available information

Marisa Fernández

Hospital de Infecciosas F. J. Muñiz, Buenos Aires, Argentina; Instituto Nacional de Parasitología Fatala Chaben, Administración Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbrán, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in JACC
Verified
Journal Article
Closed access
CMCarlos A. Morillo
Carlos A. Morillo
HWHetty Waskin
Hetty Waskin
SSSergio Sosa-Estani
Sergio Sosa-Estani
MBMaria del Carmen Bangher
Maria del Carmen Bangher
CCCarlos Cuneo
Carlos Cuneo
PRP.A. Reyes-López
P.A. Reyes-López

1 February 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MÁMaría Gabriela Álvarez
María Gabriela Álvarez
YHYolanda Hernández
Yolanda Hernández
GBGraciela Bertocchi
Graciela Bertocchi
MFMarisa Fernández
Marisa Fernández
BLBruno Lococo
Bruno Lococo
RVRodolfo Viotti
Rodolfo Viotti
There is a clinical need to test new schemes of benznidazole administration that are expected to be at least as effective as the current therapeutic scheme but safer. This study assessed a new scheme of benznidazole administration in chronic Chagas disease patients. A pilot study with intermittent doses of benznidazole at 5 mg/kg/day in two daily doses every 5 days for a total of 60 days was designed. The main criterion of response was the comparison of quantitative PCR (qPCR) findings prior to and 1 week after the end of treatment. The safety profile was assessed by the rate of suspensions and severity of adverse effects. Twenty patients were analyzed for safety, while qPCR was tested for 17 of them. The average age was 43 ± 7.9 years; 55% were female. Sixty-five percent of treated subjects showed detectable qPCR results prior to treatment of 1.45 (0.63 to 2.81) and 2.1 (1.18 to 2.78) parasitic equivalents per milliliter of blood (par.eq/ml) for kinetoplastic DNA (kDNA) qPCR and nuclear repetitive sequence satellite DNA (SatDNA) qPCR, respectively. One patient showed detectable PCR at the end of treatment (1/17), corresponding to 6% treatment failure, compared with 11/17 (65%) patients pretreatment ( P = 0.01). Adverse effects were present in 10/20 (50%) patients, but in only one case was treatment suspended. Eight patients showed mild adverse effects, whereas moderate reactions with increased liver enzymes were observed in two patients. The main accomplishment of this pilot study is the promising low rate of treatment suspension. Intermittent administration of benznidazole emerges a new potential therapeutic scheme, the efficacy of which should be confirmed by long-term assessment posttreatment.

15 April 2020 in Trials
Verified
Journal Article
Open access
PDF file
DMD. Molina-Morant
D. Molina-Morant
MFM. L. Fernández
M. L. Fernández
PBP. Bosch-Nicolau
P. Bosch-Nicolau
ESE. Sulleiro
E. Sulleiro
MBM. Bangher
M. Bangher
Israel MolinaIsrael Molina
Israel Molina
Background: Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on nonrandomized studies, and efficacy and safety of the optimal dose of BNZ have been scarcely analyzed in clinical trials. Methods/design: MULTIBENZ is a phase II, randomized, superiority, double-blind, multicenter international clinical trial. A total of 240 patients with Trypanosoma CD in the chronic phase will be recruited in four different countries (Argentina, Brazil, Colombia, and Spain). Patients will be randomized to receive BNZ 150 mg/day for 60 days, 400 mg/day for 15 days, or 300 mg/day for 60 days (comparator arm). The primary outcome is the efficacy of three different BNZ therapeutic schemes in terms of dose and duration. Efficacy will be assessed according to the proportion of patients with sustained parasitic load suppression in peripheral blood measured by polymerase chain reaction. The secondary outcomes are related to pharmacokinetics and drug tolerability. The follow-up will be 12 months from randomization to end of study participation. Recruitment was started in April 2018. Conclusion: This is a clinical trial conducted for the assessment of different dose schemes of BNZ compared with the standard treatment regimen for the treatment of CD in the chronic phase. MULTIBENZ may help to clarify which is the most adequate BNZ regimen in terms of efficacy and safety, predicated on sustained parasitic load suppression in peripheral blood. Trial registration: ClinicalTrials.gov, NCT03191162. Registered on 19 June 2017.

14 August 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SBSusana A. Besuschio
Susana A. Besuschio
APAlbert Picado
Albert Picado
AMArturo Muñoz-Calderón
Arturo Muñoz-Calderón
DWDiana P Wehrendt
Diana P Wehrendt
MFMarisa Fernández
Marisa Fernández
ASAlejandro Schijman
Alejandro Schijman
A Trypanosoma cruzi Loopamp kit was recently developed as a ready-to-use diagnostic method requiring minimal laboratory facilities. We evaluated its diagnostic accuracy for detection of acute Chagas disease (CD) in different epidemiological and clinical scenarios. In this retrospective study, a convenience series of clinical samples (venous blood treated with EDTA or different stabilizer agents, heel-prick blood in filter paper or cerebrospinal fluid samples (CSF)) from 30 infants born to seropositive mothers (13 with congenital CD and 17 noninfected), four recipients of organs from CD donors, six orally–infected cases after consumption of contaminated guava juice and six CD patients coinfected with HIV at risk of CD reactivation (N = 46 patients, 46 blood samples and 1 CSF sample) were tested by T. cruzi Loopamp kit (Tc LAMP) and standardized quantitative real-time PCR (qPCR). T. cruzi Loopamp accuracy was estimated using the case definition in the different groups as a reference. Cohen’s kappa coefficient (κ) was applied to measure the agreement between Tc LAMP (index test) and qPCR (reference test). Sensitivity and specificity of T. cruzi Loopamp kit in blood samples from the pooled clinical groups was 93% (95% CI: 77–99) and 100% (95% CI: 80–100) respectively. The agreement between Tc LAMP and qPCR was almost perfect (κ = 0.92, 95% CI: 0.62–1.00). The T. cruzi Loopamp kit was sensitive and specific for detection of T. cruzi infection. It was carried out from DNA extracted from peripheral blood samples (via frozen EDTA blood, guanidine hydrochloride-EDTA blood, DNAgard blood and dried blood spots), as well as in CSF specimens infected with TcI or TcII/V/VI parasite populations. The T. cruzi Loopamp kit appears potentially useful for rapid detection of T. cruzi infection in congenital, acute and CD reactivation due to HIV infection. The aim of this study was to evaluate a kit prototype (T. cruzi Loopamp or Tc LAMP) based on loop-mediated isothermal amplification (LAMP) for molecular diagnosis of acute Chagas disease in well-characterized individuals, collected in real life conditions, such as newborns or infants born to Chagas disease mothers aiming to detect congenital Chagas disease, recipients of organs from Chagas disease donors who acquired T. cruzi infection after transplantation, persons with oral Chagas disease acquired after consumption of a contaminated meal, and HIV/T. cruzi coinfected patients at risk of Chagas disease reactivation due to immunosuppression. Different types of clinical samples were tested; peripheral blood samples treated with ethylenediamine tetraacetic acid (EDTA) as anticoagulant or with guanidine hydrochloride or DNAgard stabilizer agents, as well as dried blood spots and cerebrospinal fluid samples. The performance of Tc LAMP was estimated using the case definition in the different groups as a reference and all test kit results were compared to those obtained using standardized duplex real-time PCR (qPCR) in the same clinical samples. Sensitivity and specificity of Tc LAMP in blood samples from the pooled clinical groups were 93% (95% CI: 77–99) and 100% (95% CI: 80–100) respectively. The agreement between Tc LAMP and qPCR was almost perfect (κ index of Cohen = 0.92, 95% CI: 0.62–1.00). Tc LAMP was sensitive and specific for detection of T. cruzi infection in the tested samples, encouraging prospective field studies to validate its use for rapid detection of T. cruzi infection in congenital, acute and CD reactivation due to HIV infection.

15 March 2016 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
MFMarisa Liliana Fernández
Marisa Liliana Fernández
MMMaria Elena Marson
Maria Elena Marson
JRJuan Carlos Ramirez
Juan Carlos Ramirez
GMGuido Mastrantonio
Guido Mastrantonio
ASAlejandro Gabriel Schijman
Alejandro Gabriel Schijman
FBFacundo García Bournissen
Facundo García Bournissen
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.

22 August 2023 in Medical Mycology Case Reports
Verified
Journal Article
Open access
FMFernando Antonio Messina
Fernando Antonio Messina
GSGabriela Santiso
Gabriela Santiso
MRMercedes Romero
Mercedes Romero
ABAlexandro Bonifaz
Alexandro Bonifaz
MFMarisa Fernandez
Marisa Fernandez
Emmanuel MarinEmmanuel Marin
Emmanuel Marin
A case of tinea corporis by Trichophyton indotineae observed in Argentina is presented. The patient had a history of having spent 18 months in Tulum, Mexico. She was suffering from tinea corporis in the anterior region of both thighs and the gluteal area. A mycological study was performed and T. mentagrophytes complex was isolated. The fungus was later identified as T. indotineae by DNA sequencing and treatment with SUBA-itraconazole was initiated with good clinical response.